Kantarjian H - Search Results

1

Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.

Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ. Cortes J, et al. Among authors: kantarjian h. Cancer Chemother Pharmacol. 2002 Dec;50(6):497-500. doi: 10.1007/s00280-002-0539-y. Epub 2002 Oct 22. Cancer Chemother Pharmacol. 2002. PMID: 12451477 Clinical Trial.

2

Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.

Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Talpaz M, et al. Among authors: kantarjian h. Cancer. 1992 Jan 15;69(2):410-2. doi: 10.1002/1097-0142(19920115)69:2<410::aid-cncr2820690222>3.0.co;2-v. Cancer. 1992. PMID: 1370212

3

Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.

Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Estey E, et al. Among authors: kantarjian h. Blood. 1992 May 1;79(9):2246-55. Blood. 1992. PMID: 1571541 Free article.

4

Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.

Keating MJ, Estey E, Kantarjian H, Plunkett W, O'Brien S, Koller C, Beran M, Freireich EJ. Keating MJ, et al. Among authors: kantarjian h. Leukemia. 1992;6 Suppl 2:78-80. Leukemia. 1992. PMID: 1578950 Review. No abstract available.

5

AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.

Estey E, Trujillo JM, Cork A, O'Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S. Estey E, et al. Among authors: kantarjian h. Hematol Pathol. 1992;6(1):43-8. Hematol Pathol. 1992. PMID: 1601822

6

CI-973, a new platinum derivative with potential antileukemic activity.

O'Brien S, Kantarjian H, Freireich E, Johnston D, Nguyen K, Beran M. O'Brien S, et al. Among authors: kantarjian h. Cancer Res. 1992 Aug 1;52(15):4130-4. Cancer Res. 1992. PMID: 1638526

7

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB. Keating MJ, et al. Among authors: kantarjian h. J Clin Oncol. 1991 Jan;9(1):44-9. doi: 10.1200/JCO.1991.9.1.44. J Clin Oncol. 1991. PMID: 1702145 Clinical Trial.

8

Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients.

Talpaz M, Chernajovsky Y, Troutman-Worden K, Wetzler M, Kantarjian H, Gutterman JU, Kurzrock R. Talpaz M, et al. Among authors: kantarjian h. Cancer Res. 1992 Mar 1;52(5):1087-90. Cancer Res. 1992. PMID: 1737366

9

Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.

O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, Keating M. O'Brien S, et al. Among authors: kantarjian h. Cancer. 1991 Aug 15;68(4):691-4. doi: 10.1002/1097-0142(19910815)68:4<691::aid-cncr2820680404>3.0.co;2-z. Cancer. 1991. PMID: 1855168

10

Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia.

Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Schilling PJ, et al. Among authors: kantarjian h. Cancer. 1991 Oct 1;68(7):1536-7. doi: 10.1002/1097-0142(19911001)68:7<1536::aid-cncr2820680713>3.0.co;2-b. Cancer. 1991. PMID: 1893353

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,541 results

Search Page

Filters